|
Real-time Estimate
Tradegate
19:52:54 15/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 126.57 EUR | +2.06% |
|
-0.45% | +18.40% |
Company Valuation: Gilead Sciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 91,081 | 107,677 | 100,942 | 115,118 | 152,281 | 181,542 | - | - |
| Change | - | 18.22% | -6.25% | 14.04% | 32.28% | 19.22% | - | - |
| Enterprise Value (EV) 1 | 118,530 | 126,522 | 118,665 | 131,838 | 169,585 | 198,287 | 190,666 | 184,376 |
| Change | - | 6.74% | -6.21% | 11.1% | 28.63% | 16.92% | -3.84% | -3.3% |
| P/E | 14.7x | 23.6x | 18x | 243x | 18.1x | -44.3x | 18.2x | 16.8x |
| PBR | 4.32x | 5.05x | 4.48x | 5.98x | 6.73x | 10.9x | 8.05x | 6.29x |
| PEG | - | -0.9x | 0.8x | -2.7x | 0x | 0x | -0x | 1.97x |
| Capitalization / Revenue | 3.34x | 3.95x | 3.72x | 4x | 5.17x | 5.91x | 5.55x | 5.29x |
| EV / Revenue | 4.34x | 4.64x | 4.38x | 4.59x | 5.76x | 6.46x | 5.83x | 5.37x |
| EV / EBITDA | 8.12x | 8.86x | 9.01x | 11.7x | 10.6x | 25.2x | 10.7x | 10.1x |
| EV / EBIT | 9.45x | 10.4x | 11.3x | 15.5x | 12.9x | 61.2x | 12x | 10.9x |
| EV / FCF | 11x | 15.2x | 16x | 12.8x | 17.9x | -376x | 14.6x | 13.3x |
| FCF Yield | 9.12% | 6.59% | 6.25% | 7.82% | 5.58% | -0.27% | 6.86% | 7.52% |
| Dividend per Share 2 | 2.84 | 2.92 | 3 | 3.08 | 3.16 | 3.291 | 3.349 | 3.012 |
| Rate of return | 3.91% | 3.4% | 3.7% | 3.33% | 2.57% | 2.25% | 2.29% | 2.06% |
| EPS 2 | 4.93 | 3.64 | 4.5 | 0.38 | 6.78 | -3.306 | 8.024 | 8.707 |
| Distribution rate | 57.6% | 80.2% | 66.7% | 811% | 46.6% | -99.5% | 41.7% | 34.6% |
| Net sales 1 | 27,305 | 27,281 | 27,116 | 28,754 | 29,443 | 30,702 | 32,682 | 34,347 |
| EBITDA 1 | 14,598 | 14,283 | 13,177 | 11,287 | 15,953 | 7,859 | 17,834 | 18,324 |
| EBIT 1 | 12,548 | 12,180 | 10,484 | 8,520 | 13,193 | 3,240 | 15,834 | 16,889 |
| Net income 1 | 6,225 | 4,592 | 5,665 | 480 | 8,510 | -4,275 | 10,275 | 10,917 |
| Net Debt 1 | 27,449 | 18,845 | 17,723 | 16,720 | 17,304 | 16,745 | 9,125 | 2,835 |
| Reference price 2 | 72.61 | 85.85 | 81.01 | 92.37 | 122.74 | 146.41 | 146.41 | 146.41 |
| Nbr of stocks (in thousands) | 1,254,384 | 1,254,244 | 1,246,042 | 1,246,266 | 1,240,680 | 1,239,955 | - | - |
| Announcement Date | 01/02/22 | 02/02/23 | 06/02/24 | 11/02/25 | 10/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 32.41x | 11.77x | 23.88x | 0.61% | 1,015B | ||
| 29.62x | 6.59x | 18.45x | 2.02% | 642B | ||
| 33.52x | 7.76x | 16.03x | 2.62% | 463B | ||
| 19.65x | 4.78x | 11.85x | 2.77% | 353B | ||
| 19.69x | 5.14x | 12.76x | 3.13% | 265B | ||
| 21.05x | 4.32x | 12.35x | 2.04% | 254B | ||
| 24.13x | 6.36x | 11.33x | 2.64% | 206B | ||
| 12.48x | 4.54x | 9.49x | 4.03% | 191B | ||
| -44.28x | 6.46x | 25.23x | 2.25% | 182B | ||
| Average | 16.47x | 6.41x | 15.71x | 2.46% | 396.69B | |
| Weighted average by Cap. | 23.59x | 7.64x | 17.62x | 2.01% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GILD Stock
- GIS Stock
- Valuation Gilead Sciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
















